PA8792501A1 - Nuevos derivados de 6-triazolopiridacina-sulfanil benzotiazol y bencimidazol,su procedimiento de preparación,su aplicación como medicamentos,composiciones farmacéuticas y nueva utilización principalmente como inhibidores de met. - Google Patents

Nuevos derivados de 6-triazolopiridacina-sulfanil benzotiazol y bencimidazol,su procedimiento de preparación,su aplicación como medicamentos,composiciones farmacéuticas y nueva utilización principalmente como inhibidores de met.

Info

Publication number
PA8792501A1
PA8792501A1 PA8792501A PA8792501A PA8792501A1 PA 8792501 A1 PA8792501 A1 PA 8792501A1 PA 8792501 A PA8792501 A PA 8792501A PA 8792501 A PA8792501 A PA 8792501A PA 8792501 A1 PA8792501 A1 PA 8792501A1
Authority
PA
Panama
Prior art keywords
phenyl
medications
new
triazolopiridacina
bencimidazol
Prior art date
Application number
PA8792501A
Other languages
English (en)
Inventor
Eva Albert
Eric Bacque
Conception Nemecek
Antonio Ugolini
Sylvie Wentzler
Original Assignee
Sanofi Aventis
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=40524792&utm_source=***_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PA8792501(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority claimed from FR0705789A external-priority patent/FR2919870B1/fr
Priority claimed from FR0801819A external-priority patent/FR2929613B1/fr
Application filed by Sanofi Aventis filed Critical Sanofi Aventis
Publication of PA8792501A1 publication Critical patent/PA8792501A1/es

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D487/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04Ortho-condensed systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50Pyridazines; Hydrogenated pyridazines
    • A61K31/5025Pyridazines; Hydrogenated pyridazines ortho- or peri-condensed with heterocyclic ring systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • A61P11/06Antiasthmatics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • A61P17/06Antipsoriatics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • A61P19/02Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00Drugs for disorders of the muscular or neuromuscular system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00Drugs for disorders of the senses
    • A61P27/02Ophthalmic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/08Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/08Antiallergic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00Drugs for disorders of the blood or the extracellular fluid
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/10Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D277/00Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/60Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings condensed with carbocyclic rings or ring systems
    • C07D277/62Benzothiazoles
    • C07D277/68Benzothiazoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached in position 2
    • C07D277/82Nitrogen atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D417/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D487/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings

Abstract

LA INVENCIÓN SE REFIERE A LOS PRODUCTOS DE FÓRMULA(1)EN LA QUE==== REPRESENTA UN ENLACE SENCILLO O DOBLE;Ra REPRESENTA H, Hal,ALCOXI, O-CICLOALQUILO,HETEROARILO,FENILO,NHCOalk,NHCOcicloalk o NR1R2;X REPRESENTA S,SO oSO2;A REPRESENTA NH O S;W REPRESENTA H,ALQUILO O COR CON R QUE REPRESENTA CICLOALQUILO;ALQUILO SUSTITUIDO OPCIONALMENTE CON NR3R4,ALCOXI,HIDROXI,FENILO,HETEROARILO O HETROCICLOALQUILO;ALCOXI SUSTITUIDO OPCIONALMENTE CON NR3R4,ES DECIR UN RADICAL O-(CH2)N-NR3R4,UN RADICAL O-FENILO O O-(CH2)N-FENILO,CON FENILO SUSTITUIDO OPCIONALMENTE Y N=1A4;O EL RADICAL NR1R2;R1 REPRESENTA H O ALK Y R2 REPRESENTA H,CICLOALQUILO O ALQUILO;R3YR4 REPRESENTA H, ALK,CICLOALQUILO,HETEROARILO O FENILO;R1,R2Y/O R3,R4 FORMAN CON N UN CICLO QUE CONTIENE OPCIONALMENTE O,S,N Y/O NH;ESTANDO TODOS LOS HETEROCICLOALQUILO,HETEROARILO Y FENILO Y CICLICOS SUSTITUIDOS OPCIONALMENTE;ESTANDO ESTOS PRODUCTOS EN TODAS LAS FORMAS ISÓMERAS Y LAS SALES,COMO MEDICAMENTOS PRINCIPALMENTE COMO INHIBIDORES DE MET.
PA8792501A 2007-08-09 2008-08-05 Nuevos derivados de 6-triazolopiridacina-sulfanil benzotiazol y bencimidazol,su procedimiento de preparación,su aplicación como medicamentos,composiciones farmacéuticas y nueva utilización principalmente como inhibidores de met. PA8792501A1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
FR0705789A FR2919870B1 (fr) 2007-08-09 2007-08-09 Nouveaux derives de 6-triazolopyridazine-sulfanyl benzothiazole et benzothiazole et benzimidazole, procede, compositions pharmaceutiques et nouvelle utilisation comme inhibiteurs de cmet
FR0801819A FR2929613B1 (fr) 2008-04-02 2008-04-02 Nouveaux derives de 6-triazolopyridazine-sulfanyl benzothiazole et benzimidazole,leur preparation,comme medicaments et utilisation notamment comme inhibiteurs de met

Publications (1)

Publication Number Publication Date
PA8792501A1 true PA8792501A1 (es) 2009-04-23

Family

ID=40524792

Family Applications (1)

Application Number Title Priority Date Filing Date
PA8792501A PA8792501A1 (es) 2007-08-09 2008-08-05 Nuevos derivados de 6-triazolopiridacina-sulfanil benzotiazol y bencimidazol,su procedimiento de preparación,su aplicación como medicamentos,composiciones farmacéuticas y nueva utilización principalmente como inhibidores de met.

Country Status (41)

Country Link
US (3) US8546393B2 (es)
EP (1) EP2178881B1 (es)
JP (1) JP5694767B2 (es)
KR (1) KR101654376B1 (es)
CN (1) CN101801973B (es)
AR (1) AR068055A1 (es)
AU (1) AU2008320791B2 (es)
BR (1) BRPI0815606A2 (es)
CA (2) CA2884102A1 (es)
CL (1) CL2008002351A1 (es)
CO (1) CO6251270A2 (es)
CR (1) CR11252A (es)
CY (1) CY1114906T1 (es)
DK (1) DK2178881T3 (es)
DO (1) DOP2010000040A (es)
EA (1) EA023465B1 (es)
EC (1) ECSP109944A (es)
ES (1) ES2436657T3 (es)
GT (1) GT201000023A (es)
HR (1) HRP20131182T1 (es)
IL (1) IL203734A (es)
JO (1) JO2935B1 (es)
MA (1) MA31685B1 (es)
ME (1) ME00972B (es)
MX (2) MX2010001593A (es)
MY (1) MY152535A (es)
NI (1) NI201000022A (es)
NZ (1) NZ583177A (es)
PA (1) PA8792501A1 (es)
PE (1) PE20090900A1 (es)
PL (1) PL2178881T3 (es)
PT (1) PT2178881E (es)
RS (1) RS53078B (es)
SG (1) SG183077A1 (es)
SI (1) SI2178881T1 (es)
TN (1) TN2010000026A1 (es)
TW (1) TWI429649B (es)
UA (1) UA101328C2 (es)
UY (1) UY31277A1 (es)
WO (1) WO2009056692A2 (es)
ZA (1) ZA201000912B (es)

Families Citing this family (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PA8792501A1 (es) 2007-08-09 2009-04-23 Sanofi Aventis Nuevos derivados de 6-triazolopiridacina-sulfanil benzotiazol y bencimidazol,su procedimiento de preparación,su aplicación como medicamentos,composiciones farmacéuticas y nueva utilización principalmente como inhibidores de met.
EA201170222A1 (ru) * 2008-07-18 2011-08-30 Санофи-Авентис НОВЫЕ ПРОИЗВОДНЫЕ ТРИАЗОЛО[4,3-a]ПИРИДИНА, СПОСОБ ИХ ПОЛУЧЕНИЯ, ИХ ПРИМЕНЕНИЕ В КАЧЕСТВЕ ЛЕКАРСТВЕННЫХ СРЕДСТВ, ФАРМАЦЕВТИЧЕСКИЕ КОМПОЗИЦИИ И НОВОЕ ПРИМЕНЕНИЕ, В ЧАСТНОСТИ, В КАЧЕСТВЕ ИНГИБИТОРОВ МЕТ
FR2945806B1 (fr) * 2009-05-19 2013-04-05 Sanofi Aventis Nouveaux derives imidazo[1,2-a]pyridine,procede de preparation,medicaments,compositions pharmaceutiques et utilisation notamment comme inhibiteurs de met
US20110257171A1 (en) * 2008-07-18 2011-10-20 Sanofi-Aventis Novel imidazo[1,2-a]pyridine derivatives, method for the preparation thereof, use thereof as medicaments, pharmaceutical compositions and novel use in particular as met inhibitors
FR2941229B1 (fr) * 2009-01-21 2012-11-30 Sanofi Aventis Nouveaux derives triazolo°4,3-a!pyridine, leur procede de preparation, leur application a titre de medicaments, compositions pharmaceutiques et nouvelle utilisation notamment comme inhibiteurs de met
UY32049A (es) 2008-08-14 2010-03-26 Takeda Pharmaceutical Inhibidores de cmet
FR2941949B1 (fr) * 2009-02-06 2011-04-01 Sanofi Aventis Derives de 6-(6-o-cycloalkyl ou 6-nh-cycloalkyl- triazolopyridazine-sulfanyl)benzothiazoles et benzimidazoles preparation, application comme medicaments et utilisation comme inhibiteurs de met.
FR2941952B1 (fr) * 2009-02-06 2011-04-01 Sanofi Aventis Derives de 6-(6-substitue-triazolopyridazine-sulfanyl) 5-fluoro-benzothiazoles et 5-fluoro-benzimidazoles : preparation, application comme medicaments et utilisation comme inhibiteurs de met.
FR2941951B1 (fr) * 2009-02-06 2011-04-01 Sanofi Aventis Derives de 6-(6-nh-substitue-triazolopyridazine-sulfanyl) benzothiazoles et benzimidazoles : preparation, application comme medicaments et utilisation comme inhibiteurs de met.
FR2941950B1 (fr) * 2009-02-06 2011-04-01 Sanofi Aventis Derives de 6-(6-o-substitue-triazolopyridazine-sulfanyl) benzothiazoles et benzimidazoles : preparation, application comme medicaments et utilisation comme inhibiteurs de met.
KR20110113755A (ko) * 2009-02-10 2011-10-18 아스트라제네카 아베 트리아졸로 〔4,3-b〕 피리다진 유도체 및 전립샘암에 대한 이의 용도
MX2011012055A (es) * 2009-05-11 2011-12-06 Astrazeneca Ab [1,2,4] triazolo [4,3-b] piridazinas como ligandos del receptor de androgeno.
NZ601128A (en) 2009-12-31 2014-12-24 Hutchison Medipharma Ltd Certain triazolopyridines and triazolopyrazines, compositions thereof and methods of use therefor
FR2958292A1 (fr) * 2010-03-30 2011-10-07 Sanofi Aventis Derives de 6-(alkyl- ou cycloalkyl-triazolopyridazine-sulfanyl) benzothiazoles: preparation, application comme medicaments et utilisation comme inhibiteurs de met
TW201202242A (en) 2010-03-30 2012-01-16 Sanofi Aventis 6-(alkyl-or cycloalkyl-triazolopyridazine-sulfanyl)benzo-thiazole derivatives: preparation, and use as medicaments and as MET inhibitors
FR2966151B1 (fr) * 2010-10-14 2012-11-09 Sanofi Aventis Derives de 6-(alkyl- ou cycloalkyl-triazolopyridazine-sulfanyl) benzothiazoles: preparation, application comme medicaments et utilisation comme inhibiteurs de met
EP2588107A1 (en) 2010-07-01 2013-05-08 Takeda Pharmaceutical Company Limited COMBINATION OF A cMET INHIBITOR AND AN ANTIBODY TO HGF AND/OR cMET
AR085183A1 (es) 2010-07-30 2013-09-18 Lilly Co Eli Compuesto 6-(1-metil-1h-pirazol-4-il)-3-(2-metil-2h-indazol-5-iltio)-[1,2,4]triazol[4,3-b]piridazina, composicion farmaceutica que lo comprende y uso para preparar un medicamento util para tratar cancer
UA117092C2 (uk) 2011-09-06 2018-06-25 Байєр Інтеллектуал Проперті Гмбх Амінозаміщені імідазопіридазини
ES2691650T3 (es) 2011-09-15 2018-11-28 Novartis Ag 3-(quinolin-6-il-tio)-[1,2,4]-triazolo-[4,3-a]-piridinas 6-sustituidas como inhibidores de tirosina quinasa c-Met
JP2015525754A (ja) 2012-07-12 2015-09-07 サノフイ 化合物1−(6−{[6−(4−フルオロフェニル)[1,2,4]トリアゾロ[4,3−b]ピリダジン−3−イル]スルファニル}−1,3−ベンゾチアゾール−2−イル)−3−(2−モルホリン−4−イルエチル)尿素を含む抗腫瘍組成物
ES2646916T3 (es) 2012-11-19 2017-12-18 Bayer Pharma Aktiengesellschaft Aminoimidazopiridazinas como inhibidores de MKNK1 cinasa
TWI695837B (zh) 2014-12-04 2020-06-11 比利時商健生藥品公司 作為激酶調節劑之***並嗒
WO2016091891A1 (en) 2014-12-09 2016-06-16 INSERM (Institut National de la Santé et de la Recherche Médicale) Human monoclonal antibodies against axl
WO2016135041A1 (en) 2015-02-26 2016-09-01 INSERM (Institut National de la Santé et de la Recherche Médicale) Fusion proteins and antibodies comprising thereof for promoting apoptosis
US10047071B1 (en) 2018-01-15 2018-08-14 King Saud University Dihydropyrimidinone derivatives
CN110317216A (zh) * 2018-03-28 2019-10-11 首都医科大学 一种***并哒嗪类衍生物在医药领域的应用
CN114364798A (zh) 2019-03-21 2022-04-15 欧恩科斯欧公司 用于治疗癌症的Dbait分子与激酶抑制剂的组合
CN110041311B (zh) * 2019-05-20 2021-03-19 东南大学 一种荧光探针分子ml-fp及其制备方法和应用
EP3983086A1 (en) * 2019-06-12 2022-04-20 Bristol-Myers Squibb Company Crystalline salt forms of 6-(cyclopropanecarboxamido)-4-((2-methoxy-3-(1-methyl-1h-1,2,4-triazol-3-yl)phenyl)amino)-n-(methyl-d3) pyridazine-3-carboxamide
AU2020378630A1 (en) 2019-11-08 2022-05-26 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods for the treatment of cancers that have acquired resistance to kinase inhibitors
WO2021148581A1 (en) 2020-01-22 2021-07-29 Onxeo Novel dbait molecule and its use

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2499995A1 (fr) 1981-02-13 1982-08-20 Roussel Uclaf Nouvelles oximes derivees de l'acide 3-alkyloxy ou 3-alkylthiomethyl 7-amino thiazolylacetamido cephalosporanique, leur preparation, leur application comme medicaments, les compositions les renfermant et les nouveaux intermediaires obtenus.
KR20010085780A (ko) * 1998-09-11 2001-09-07 로즈 암스트롱, 크리스틴 에이. 트러트웨인 Hiv 프로테아제 억제제
EP1298125A1 (en) 2001-09-26 2003-04-02 Aventis Pharma S.A. Substituted benzimidazole compounds and their use for the treatment of cancer
WO2007064797A2 (en) * 2005-11-30 2007-06-07 Vertex Pharmaceuticals Incorporated Inhibitors of c-met and uses thereof
CN101374843B (zh) * 2005-12-21 2012-09-05 詹森药业有限公司 作为酪氨酸激酶调节剂的***并哒嗪
EP2032578A2 (en) * 2006-05-30 2009-03-11 Pfizer Products Incorporated Triazolopyridazine derivatives
PE20080403A1 (es) * 2006-07-14 2008-04-25 Amgen Inc Derivados heterociclicos fusionados y metodos de uso
JP5378222B2 (ja) * 2006-10-23 2013-12-25 エスジーエックス ファーマシューティカルズ、インコーポレイテッド タンパク質キナーゼ調節物質としての二環式トリアゾール
PA8792501A1 (es) 2007-08-09 2009-04-23 Sanofi Aventis Nuevos derivados de 6-triazolopiridacina-sulfanil benzotiazol y bencimidazol,su procedimiento de preparación,su aplicación como medicamentos,composiciones farmacéuticas y nueva utilización principalmente como inhibidores de met.

Also Published As

Publication number Publication date
KR20100065319A (ko) 2010-06-16
WO2009056692A3 (fr) 2009-06-25
CN101801973B (zh) 2014-03-12
NI201000022A (es) 2010-03-11
CA2884102A1 (fr) 2009-05-07
US9115134B2 (en) 2015-08-25
CL2008002351A1 (es) 2009-10-23
JP5694767B2 (ja) 2015-04-01
CO6251270A2 (es) 2011-02-21
CN101801973A (zh) 2010-08-11
CR11252A (es) 2010-06-21
JP2010535747A (ja) 2010-11-25
CA2695628C (fr) 2016-11-22
KR101654376B1 (ko) 2016-09-05
BRPI0815606A2 (pt) 2015-03-03
WO2009056692A2 (fr) 2009-05-07
US20150344484A1 (en) 2015-12-03
MA31685B1 (fr) 2010-09-01
JO2935B1 (en) 2016-03-15
ECSP109944A (es) 2010-03-31
AR068055A1 (es) 2009-11-04
EP2178881B1 (fr) 2013-10-02
RS53078B (en) 2014-06-30
EP2178881A2 (fr) 2010-04-28
GT201000023A (es) 2012-04-03
IL203734A (en) 2014-12-31
AU2008320791B2 (en) 2013-10-10
PL2178881T3 (pl) 2014-03-31
NZ583177A (en) 2012-03-30
US20100298315A1 (en) 2010-11-25
UA101328C2 (uk) 2013-03-25
MY152535A (en) 2014-10-15
UY31277A1 (es) 2009-03-31
MX2010001593A (es) 2010-10-04
AU2008320791A1 (en) 2009-05-07
ME00972B (me) 2012-06-20
US20140005189A1 (en) 2014-01-02
TWI429649B (zh) 2014-03-11
TW200911816A (en) 2009-03-16
SI2178881T1 (sl) 2014-01-31
ES2436657T3 (es) 2014-01-03
PE20090900A1 (es) 2009-08-06
US9321777B2 (en) 2016-04-26
HRP20131182T1 (hr) 2014-01-17
US8546393B2 (en) 2013-10-01
ZA201000912B (en) 2011-04-28
CY1114906T1 (el) 2016-12-14
TN2010000026A1 (fr) 2011-09-26
CA2695628A1 (fr) 2009-05-07
EA201070235A1 (ru) 2010-08-30
PT2178881E (pt) 2013-12-26
EA023465B1 (ru) 2016-06-30
MX340060B (es) 2016-06-23
DOP2010000040A (es) 2010-03-31
DK2178881T3 (da) 2014-01-13
SG183077A1 (en) 2012-08-30

Similar Documents

Publication Publication Date Title
PA8792501A1 (es) Nuevos derivados de 6-triazolopiridacina-sulfanil benzotiazol y bencimidazol,su procedimiento de preparación,su aplicación como medicamentos,composiciones farmacéuticas y nueva utilización principalmente como inhibidores de met.
ECSP078064A (es) NUEVOS DERIVADOS de 2,4-DIANILINOPIRIMIDINAS, SU PREPARACIÓN, COMO MEDICAMENTOS, COMPOSICIONES FARMACÉUTICAS Y PRINCIPALMENTE COMO INHIBIDORES DE IKK
UY31468A1 (es) Derivados bis-(sulfonilamino) en terapia 065
PA8798901A1 (es) Nuevos derivados de 6- aril/heteroalquiloxi benzotiazol y bencimidazol, su procedimiento de preparacion, su aplicacion como medicamentos, composiciones farmaceuticas y nueva utilizacion principalmente como inhibidores de cmet"
AR058348A1 (es) Derivados de 1-aza-biciclo-nonano y composiciones farmaceuticas que los comprenden
CY1113267T1 (el) Παραγωγα θειοφαινιου ως αγωνιστες των υποδοσεων s1p1/edg1
CO6331463A2 (es) Nuevos derivados de triazolo(4,3-a)piridina, su procedimiento de preparacion, su aplicacion como medicamentos, composiciones farmaceuticas y nueva utilizacion particularmente como inhibidores de met
UY30105A1 (es) Derivados nuevos azufrados de urea cíclica, su preparación y su utilización farmacéutica como inhibidores de quinasas.
CO6331467A2 (es) Nuevos derivados de imidazo(1,2-a)piridina, su procedimiento de preparacion, su aplicacion como medicamentos, composiciones farmaceuticas y nueva utilizacion particularmente como inhibidores de met
SV2011003811A (es) Nuevos derivados de imidazo[1,2-a] pirimidina, su procedimiento de preparacion, su aplicacion como medicamentos, composiciones farmaceuticas y nueva utilizacion particularmente como inhibidores de met
CU23761B7 (es) Nuevos derivados de diosmetina, su procedimiento de preparación y las composiciones farmacéuticas que los contienen
CU20100157A7 (es) Nuevos derivados dihidroindolonas, su procedimiento de preparación y las composiciones farmacéuticas que los contienen
CR10206A (es) Acidos4-fenil-tiazol-5-carboxilicos amidas de acidos 4-fenil-tiazol-5-carboxilicos como inhibidores de la plk1
AR075892A1 (es) Derivados de benzotiadiazepinas, su procedimiento de preparacion y composiciones farmaceuticas que los contienen
SV2009003348A (es) Nuevos derivados triciclicos, su procedimiento de preparacion y las composiciones farmaceuticas que lo contienen
CO6420339A2 (es) Derivados de 6-(6-sustituido-triazolopiridacina-sulfanil) 5-fluoro-benzotiazoles y 5-fluoro-bencimidazoles : preparación, aplicación como medicamentos y utilización como inhibidores de met
CO6280537A2 (es) Nuevos derivados de pirroloindol inhibidores de hsp90 composiciones que los contienen y utilizacion
AR075250A1 (es) Derivados de 6-(triazolopiridazinsulfanil sustituido en 6-nh)benzotiazoles y bencimidazoles; preparacion, aplicacion como medicamentos y utilizacion como inhibidores de met.
CO6400223A2 (es) Derivados de 6-(6-o-sustituido-triazolopiridazina-sulfanil)benzotiazoles y bencimidazoles : preparación, aplicación como medicamentos y utilización como inhibidores de met
CU20100149A7 (es) Nuevos derivados croménicos, su procedimiento de preparación y las composiciones farmacéuticas que los contienen
PA8796701A1 (es) Nuevas sales de adicion de inhibidores de la enzima de conversion de la angiotensina a acidos donadores de no su procedimiento de preparacion y las composiciones farmaceuticas que las contienen
DOP2018000165A (es) Nuevos derivados de fosfinanos y azafosfinanos, su procedimiento de preparación y las composiciones farmacéuticas que los contienen
CO6400222A2 (es) Derivados de 6-(6-o-cicloalquil o de 6-nh-cicloalquil-triazolopiridazina-sulfanil) benzotiazoles y bencimidazoles:preparación, aplicación como medicamentos y utilización como inhibidores de la met
CU20130037A7 (es) Nuevos derivados dihidrobenzoxatiazepinas, su procedimiento de preparación y las composiciones farmacéuticas que los contienen
UY33927A (es) Nuevos derivados dihidro-oxazolobenzodiazepinonas, su procedimiento de preparación y las composiciones farmacéuticas que los contienen